Kathy Dietlin, MD
Allergy & Immunology · North Dartmouth, MANPI 1699734756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 702 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 30.0% of the total. Reporting peaked in 2023 at $3,345 and has fallen 99.4% since, to $21 in 2025.
Across 702 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$734
- Takeda Pharmaceuticals U.S.A., Inc.$687
- plus $5K from 25 others
What the payments were for
- Food & beverage$14,127100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 185 | $4,244 |
| GSK | 92 | $1,663 |
| Sanofi | 43 | $1,097 |
| Regeneron Healthcare Solutions, Inc. | 43 | $1,043 |
| CSL Behring | 33 | $734 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $687 |
| Novartis | 44 | $626 |
| Genentech USA, Inc. | 49 | $524 |
| Boehringer Ingelheim | 21 | $445 |
| Pharming Healthcare, Inc. | 19 | $426 |
| Pfizer | 23 | $385 |
| Teva Pharmaceuticals USA, Inc. | 14 | $293 |
| Kaleo, Inc. | 17 | $283 |
| AbbVie | 11 | $272 |
| Biocryst US Sales Co., LLC | 10 | $217 |
| LEO Pharma Inc. | 7 | $177 |
| Aimmune Therapeutics, Inc. | 8 | $157 |
| Shire North American Group Inc | 12 | $141 |
| Amgen | 7 | $138 |
| Covis Pharma GmbH | 7 | $127 |
| Optinose US, Inc. | 5 | $105 |
| Octapharma USA, Inc. | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $63 |
| Alk-abello, Inc | 3 | $44 |
| Incyte Corporation | 2 | $43 |
| Mylan Pharmaceuticals Inc. | 2 | $35 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Merck | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$627
- SYMBICORT$485
- TEZSPIRE$403
- BREZTRI$403
- TUDORZA PRESSAIR$261
- BEVESPI AEROSPHERE$224
- FARXIGA$142
- BREZTRI AEROSPHERE$104
How this compares
$14,134 in reported general payments places this provider in the 70th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 19 | $70,964 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $20,901 |
| Arnuity ElliptaFluticasone Furoate | 77 | $17,506 |
| Spiriva RespimatTiotropium Bromide | 21 | $12,061 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $9,433 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $5,852 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,339 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,890 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $3,139 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $2,935 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $2,443 |
| Ventolin HfaAlbuterol Sulfate | 41 | $2,443 |
| Fluticasone Propionate | 115 | $2,017 |
| Montelukast Sodium | 96 | $1,504 |
| Azelastine Hcl | 58 | $1,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArnuity Ellipta, Breo Ellipta, Incruse Ellipta | $1,663 | $31,829113 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,244 | $26,24142 claims |
| Boehringer IngelheimSpiriva Respimat | $445 | $12,06121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in North Dartmouth
- Alan KatzNorth Dartmouth$20K
- S David MillerNorth Dartmouth$13K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.